Status:
RECRUITING
Prospective Monocentric Clinical-biological Database
Lead Sponsor:
Institut du Cancer de Montpellier - Val d'Aurelle
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pancreatic adenocarcinoma (PA) is a solid cancer with a very poor prognosis with overall survival, all stages combined, not exceeding 5% at 5 years. The incidence and number of deaths caused by this t...
Detailed Description
Pancreatic adenocarcinoma (PA) is a solid cancer with a very poor prognosis with overall survival, all stages combined, not exceeding 5% at 5 years. The incidence and number of deaths caused by this t...
Eligibility Criteria
Inclusion
- Patient over the age of 18;
- Patient managed for pancreatic adenocarcinoma;
- Patient eligible for at least one (or more) surgery (s) and chemotherapy;
- Patient giving informed consent
Exclusion
- Patient not affiliated to a social security scheme;
- Pregnant and / or nursing patient;
- Patient under guardianship, curatorship or safeguard of justice;
- Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons.
Key Trial Info
Start Date :
May 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2034
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04136132
Start Date
May 15 2019
End Date
June 1 2034
Last Update
February 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Régional du Cancer de Montpellier
Montpellier, Occ, France, 34298